Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson (NYSE:JNJ)

101.82
Delayed Data
As of Feb 12
 +0.12 / +0.12%
Today’s Change
81.79
Today|||52-Week Range
105.49
-0.88%
Year-to-Date
Achillion Begins Study on First Complement Factor D Inhibitor
Feb 12 / Zacks.com
2 Beaten-Down Biotech Stocks to Buy in February
Feb 06 / MotleyFool.com
Dow 30 Stock Roundup: Beats at Cisco, Coke; ESPN Blues Mar Disney Q4
Feb 12 / Zacks.com
If You're in Your 60s, Consider Buying These 3 Stocks
Feb 06 / MotleyFool.com
5 Charts Show Why Someone Could Buy TransEnterix
Feb 12 / MotleyFool.com
U.S. exports drop for first time since Great Recession
Feb 05 / CNNMoney.com
Jim Cramer's 'Mad Money' Recap: Don't Panic, Start Buying
Feb 11 / TheStreet.com
String of Q4 Earnings Beat Fails to Revive Pharma ETFs
Feb 05 / Zacks.com
Why Shares of Geron Corp. Cratered in January
Feb 11 / MotleyFool.com
Why Isnbt Johnson & Johnson Making More Acquisitions?
Feb 05 / MotleyFool.com
Cramer: Hail to Those Who Choose Wisely
Feb 11 / TheStreet.com
2 Numbers in Merck's 4th-Quarter Report That Have Investors Worried
Feb 04 / MotleyFool.com
Stryker (SYK) Set to Acquire Synergetics' Neuro Portfolio
Feb 11 / Zacks.com
Why Achillion Pharmaceuticals Shares Crashed 37% in January
Feb 04 / MotleyFool.com
25 Top Ranked Stocks Increasing Dividends For Decades
Feb 11 / TheOnlineInvestor.com
Smith & Nephew says results prove it can rival big groups
Feb 04 / FT.com
Top 25 S.A.F.E. Dividend Stocks
Feb 11 / DividendChannel.com
Activist investors: hard drugs
Feb 04 / FT.com
Why Incyte's Shares Are Tumbling Today
Feb 11 / MotleyFool.com
Activist Investors Are Taking Aim at the Largest Healthcare Company on Earth
Feb 04 / MotleyFool.com
This FDA Panel Decision Just Changed the Game
Feb 11 / MotleyFool.com
One Big Threat to Johnson & Johnson's Future
Feb 03 / MotleyFool.com
Here's Everything Chipotle Has Done to Handle Its E. Coli Crisis; Is it Enough?
Feb 10 / MotleyFool.com
Will 2016 Be Amgen Inc.'s Best Year Yet?
Feb 03 / MotleyFool.com
Johnson & Johnson (JNJ) Stock Closed Down, Pfizer Developing Biosimilar
Feb 10 / TheStreet.com
GlaxoSmithKline rules out break up as new drugs boost sales
Feb 03 / FT.com
Pfizer's Biosimilar of Remicade Recommended for Approval
Feb 10 / Zacks.com
Why Medivation, Inc. Shares Crashed 32% in January
Feb 03 / MotleyFool.com
Why Shares of TransEnterix Plunged Today
Feb 10 / MotleyFool.com
Oil crash could kill Exxon's perfect AAA rating
Feb 02 / CNNMoney.com
Trending Tickers: DIS, BAC, JNJ, PFE
Feb 10 / TheStreet.com
The 1 Dividend Stock I Want to Own in 2016
Feb 02 / MotleyFool.com
U.S. Futures Tick Higher as Janet Yellen Worries Over Economy
Feb 10 / TheStreet.com
Top Stocks for Retirees
Feb 02 / MotleyFool.com
1 Chart That's Bringing Big Smiles to America's Largest Companies
Feb 09 / MotleyFool.com
J&J and GSK join Medicxi's European life sciences push
Feb 02 / FT.com
3 Health Care Stocks On The Rise
Feb 08 / TheStreet.com
These Drugs Are Actually Moving The Needle For Johnson & Johnson
Feb 01 / MotleyFool.com
Frontrunning: February 8
Feb 08 / Investing Channel
Why TransEnterix, Inc. Shares Are Soaring Today
Feb 01 / MotleyFool.com
Companies Come Under More Pressure to Cut Costs and Boost Share Buybacks
Feb 08 / TheStreet.com
Investor calls for big pharma to slim down grow louder
Feb 01 / FT.com
Global currency collapse: Winners and losers
Feb 08 / CNNMoney.com
The Single Best Stock to Own Today
Feb 01 / MotleyFool.com
3 Potential Blockbusters Moving the Needle for Big Pharma in 2016
Feb 07 / MotleyFool.com
The Zacks Analyst Blog Highlights: Caterpillar, McDonald's, 3M, Procter & Gamble and ...
Feb 01 / Zacks.com
Biogen Inc. Takes Aim at Johnson & Johnson
Feb 07 / MotleyFool.com
Lasting lessons for smug CEOs and somnolent shareholders
Feb 01 / FT.com
Shares of Incyte Corporation Plummeted in January -- Here's Why
Feb 07 / MotleyFool.com
Johnson & Johnson Wants Investors to Ignore Falling Hepatitis C Drug Sales
Jan 31 / MotleyFool.com